Phenotypic and genotypic analysis of anti-tuberculosis drug resistance in mycobacterium tuberculosis isolates in Myanmar

Annals of Laboratory Medicine

Volumn 35, Issue 5, 2015, Pages 494-499

  Aung, Wah Wah ^a   Ei, Phyu Win ^a   Nyunt, Wint Wint ^b   Swe, Thyn Lei ^b   Lwin, Thandar ^b   Htwe, Mi Mi ^a   Kim, Kyung Jun ^c   Lee, Jong Seok ^d   Kim, Chang Ki ^e   Cho, Sang Nae ^f   Song, Sun Dae ^d   Chang, Chulhun L ^c,g  

^a Ministry of Health   (Myanmar)

^b National AIDS Program   (Myanmar)

^c Pusan National University School of Medicine   (South Korea)

^d International Tuberculosis Research Center   (South Korea)

^e Korean Institute of Tuberculosis   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g Pusan National University Yangsan Hospital   (South Korea)

Author keywords

Drug; Genotype; Myanmar; Mycobacterium tuberculosis; Resistance

Indexed keywords

BACTERIAL DNA; TUBERCULOSTATIC AGENT;

ADULT; DRUG EFFECTS; FEMALE; GENETICS; GENOTYPE; HUMAN; ISOLATION AND PURIFICATION; MALE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; MYANMAR; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; POLYMERASE CHAIN REACTION; SPUTUM; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GENOTYPE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYANMAR; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; POLYMERASE CHAIN REACTION; SPUTUM; TUBERCULOSIS;

EID: 84942256173     PISSN: 22343806     EISSN: 22343814     Source Type: Journal    
DOI: 10.3343/alm.2015.35.5.494     Document Type: Article

References (22)

1. World Health Organization. Global Tuberculosis Report 2012. WHO/HTM/TB/2012.6. Geneva: WHO, 2012.
2. Agonafir M, Lemma E, Wolde-Meskel D, Goshu S, Santhanam A, Girmachew F, et al. Phenotypic and genotypic analysis of multidrug-resistant tuberculosis in Ethiopia. Int J Tuberc Lung Dis 2010;14:1259-65.
3. World Health Organization. Policy Statement. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Geneva: WHO, 2008. http://www.who.int/tb/features-archive/policy-statement.pdf (Updated on 27 June 2008).
4. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2005;43:3699-703.
5. World Health Organization. Laboratory services in tuberculosis control. Culture Part III 1998; WHO/TB/98.258. Geneva: WHO, 1998.
6. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. WHO/CDS/CSR/RMD/2003. Geneva: WHO, 2003. Available from http://whqlibdoc.who.int/publications/2003/ 9241546336.pdf.
7. Viera AJ and Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med 2005;37:360-3.
8. World Health Organization. Management of MDR-TB: a field guide. WHO/HTM/TB/2008.402a. Geneva: WHO, 2009.
9. Ti T, Lwin T, Phyu S, Aung WW, Khaing TMM, Min A, et al. Magnitude of the MDR-TB problem among patients attending Yangon Divisional TB Centre, Myanmar. Myanmar Med J 2007;50:2-7.
10. Phyu S, Ti T, Jureen R, Hmun T, Myint H, Htun A, et al. Drug-resistant Mycobacterium tuberculosis among new tuberculosis patients,Yangon, Myanmar. Emerg Infect Dis 2003; 9:274-6.
11. Ti T, Lwin T, Mar TT, Maung W, Noe P, Htun A, et al. National anti-tuberculosis drug resistance survey, 2002 in Myanmar. Int J Tuberc Lung Dis 2006;10:1111-6.
12. Aung WW, Ti T, Than KK, ThidaM, Nyein MM, Htun YY, et al. Study of drug resistant cases among new pulmonary tuberculosis patients attending a tuberculosis center, Yangon, Myanmar. Southeast Asian J Trop Med Public Health 2007;38:104-10.
13. National Tuberculosis Programme, Myanmar. Annual Report 2012. Ministry of Health, Myanmar: NTP, October 2014.
14. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, et al. Trends of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 2007;11:571-6.
15. Telenti A, Imboden F, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-50.
16. Ozturk CE, Sanic K, Kaya D, Ceyhan I. Molecular analysis of isoniazid, rifampin and streptomycin resistance in Mycobacterium tuberculosis isolates from patients with tuberculosis in Düzce, Turkey. Jpn J Infect Dis 2005;58:309-12.
17. Ahmad S and Mustafa AS. Molecular diagnosis of drug resistant tuberculosis. Kuwait Med J 2001;33:120-6. Available from http://www.researchgate.net/profile/Abu-Mustafa/publication/230667668-Molecular-diagnosis-of-drug-resistant-tuberculosis.
18. Baker LV, Brown JT, Maxwell O, Gibson AL, Fang Z, Yates MD, et al. Molecular analysis of isoniazid-resistant Mycobacterium tuberculosis isolates from England and Wales reveals the phylogenetic significance of the ahpC-46A polymorphism. Antimicrob Agents Chemother 2005; 49:1455-64.
19. Hillemann D, Rüsch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007;45:2635-40.
20. Causse M, Ruiz P, Gutierrez JB, Zerolo J, Casal M. Evaluation of new GenoType MTBDRplus for detection of resistance in cultures and direct specimens of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008; 12:1456-60.
21. Huyen MN, Tiemersma EW, Lan NT, Cobelens FG, Dung NH, Sy DN, et al. Validation of the GenoTypenMTBDRplus assay for the diagnosis of multidrug resistant tuberculosis in South Vietnam. BMC Infect Dis 2010;10:149.
22. Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infect Dis 2012;12-37.